RxDoctor Payments Data

Jennifer Boody, PA

Physician Assistant · Uniondale, NYNPI 1134695828

Payments from drug & device makers

$2,751in general payments, 2019–2025

Across 149 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$973
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$339
  • Takeda Pharmaceuticals U.S.A., Inc.$184
  • Johnson & Johnson$164
  • Ironwood Pharmaceuticals, Inc$142
  • Novo Nordisk$125
  • plus $824 from 16 others

What the payments were for

  • Food & beverage$2,751100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,751 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$70,966
Medicare patients
535
Services billed
625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase13$61,688
LinzessLinaclotide49$50,206
Mesalamine14$12,733
Dexlansoprazole DrDexlansoprazole18$5,016
Vancomycin Hcl12$2,946
Pantoprazole Sodium206$2,789
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates33$1,979
Famotidine201$1,959
Omeprazole171$1,741
CholestyramineCholestyramine (With Sugar)15$926
Sucralfate24$680
Rabeprazole Sodium11$575
Hydrocortisone16$508
Dicyclomine Hcl23$482
Ciprofloxacin Hcl13$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$973$111,89462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Uniondale

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →